Stephen W Fesik

This inventor holds 33 USPTO granted patents and 12 published patent applications, plus 7 CIPO patents and 6 EPO patents, primarily in Cancer Therapeutics. Top assignees: Vanderbilt University, Abbott Laboratories Corporation, Boehringer Ingelheim International Gmbh. Active years: 1997-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephen W Fesik. Retrieved from https://idiyas.com/inventor/stephen-w-fesik

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 12)

% Patents Active = 93.9

CIPO Patents = 7 (Patent Applications = 4)

EPO Patents = 6 (Patent Applications = 15)

Average Co-Inventor Count = 5.9

ph-index = 8

Forward Citations = 224(Granted Patents)

Location History:

Gurnee, IL (US) (1997 - 2010)
Nashville, TN (US) (2018 - 2024)

Company Filing History:

21 out of 1,221

Vanderbilt University

patents

12 out of 4,188

Abbott Laboratories Corporation

patents

1 out of 1,562

Boehringer Ingelheim International Gmbh

patents

where one patent can have more than one assignee

Years Active: 1997-2026

Loading Chart...

Areas of Expertise:

WDR5 Inhibitors

Mcl-1 Inhibitors

Nuclear Magnetic Resonance

Matrix Metalloproteinases

Apoptosis Promoters

Quinazoline Compounds

Indole Derivatives

Cancer Treatment

Ligand Design

Biochemical Precursors

Isotopically-Labeled Proteins

Biphenyl Hydroxamates

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12692249 - WDR5 inhibitors and modulators (2026-07-28),

2. 12577227 - WDR5 inhibitors and modulators (2026-03-17),

3. 12545649 - WDR5-MYC inhibitors (2026-02-10),

4. 12398097 - WDR5-MYC inhibitors (2025-08-26),

5. 12195472 - Substituted indole Mcl-1 inhibitors (2025-01-14),

6. 12144816 - Substituted indole Mcl-1 inhibitors (2024-11-19),

7. 12060367 - Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer (2024-08-13),

8. 11999716 - WDR5 inhibitors and modulators (2024-06-04),

9. 11596639 - Substituted indole Mcl-1 inhibitors (2023-03-07),

10. 11318137 - Quinazoline compounds as modulators of Ras signaling (2022-05-03),

11. 11208415 - Substituted indole Mcl-1 inhibitors (2021-12-28),

12. 10954193 - Substituted indole Mcl-1 inhibitors (2021-03-23),

13. 10844044 - WDR5 inhibitors and modulators (2020-11-24),

14. 10844032 - Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors (2020-11-24),

15. 10807959 - WDR5-MLL1 inhibitors and modulators (2020-10-20),

Title: The Inventive Mind of Stephen W Fesik: Promoting Apoptosis Through Innovation

Introduction:

Stephen W Fesik, a prolific inventor hailing from Gurnee, IL (US), has made significant strides in the field of promoting apoptosis through his groundbreaking patents. With a total of 12 patents under his belt, Fesik's work exemplifies innovation at its finest.

Latest Patents:

Fesik's latest patents revolve around N-acylsulfonamide apoptosis promoters. Specifically, N-Benzoyl arylsulfonamides that function as BCL-Xl inhibitors, proving to be instrumental in promoting apoptosis. These inventions highlight Fesik's commitment to advancing medical research and improving treatments for various conditions.

Career Highlights:

A key figure at Abbott Laboratories Corporation, Fesik has not only contributed extensively to the field of apoptosis promotion but has also played a vital role in shaping the company's innovative strategies. His expertise and dedication have undoubtedly left a lasting impact on the field of biomedical research.

Collaborations:

In his professional journey, Fesik has had the privilege of collaborating with notable individuals in the industry. Some of his coworkers, such as Philip J Hajduk and David John Augeri, have worked alongside him, contributing to the success of various projects and patents.

Conclusion:

Stephen W Fesik's remarkable career as an inventor stands as a testament to his unwavering dedication to pushing the boundaries of scientific discovery. His inventive spirit and commitment to excellence continue to inspire advancements in the realm of promoting apoptosis, ultimately benefitting countless individuals worldwide.

Profile summary based on public USPTO records.